Hematologic Malignancies Program ABSTRACT The goal of the Hematologic Malignancies (HM) Program is to improve outcomes and expand opportunities for patients with leukemia, Hodgkin and non-Hodgkin lymphoma, and multiple myeloma by integrating basic, translational, and clinical research through close collaborations among investigators in the Program. Research collaborations are facilitated through disease- and modality-specific research teams that meet regularly, including leukemia, lymphoma, multiple myeloma, transplant, immunotherapy, and gene therapy. Each of these teams works in an integrated manner and includes multi-disciplinary collaborators from the HM Program as well as from other Cancer Center programs and cores. The Themes of our program are the following: Theme 1: Identify key biological pathways and targeting strategies for hematologic malignancies. Theme 2: Develop novel therapeutic approaches for early-phase clinical testing. Theme 3: Advance translational research in hematopoietic cell transplantation (HCT) and adoptive cellular immunotherapy (ACIT). The HM Program improves public health both through its refinement of currently available treatment options for hematological malignancies and its advancement of novel therapies to the clinic, via an intensive Phase I/II investigational drug program. We are exploring multiple avenues of treatment ? chemotherapy, immunotherapy, gene therapy, targeted therapy, chimeric antigen receptor T cell therapy and HCT ? to improve patient cure rates and treatment tolerability throughout the disease course. Membership: 37 Program Members representing 8 basic and clinical departments Publications: 319 total. 29.2% intra-programmatic; 35.1% inter-programmatic; 45.5% inter-institutional Funding: $6,409,859 peer-reviewed; $3,670,074 of which is NCI funding

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-37
Application #
9849213
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Oh, Eunjin; Ahn, Miwon; Afelik, Solomon et al. (2018) Syntaxin 4 Expression in Pancreatic ?-Cells Promotes Islet Function and Protects Functional ?-Cell Mass. Diabetes 67:2626-2639
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2018) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs 41:506-512
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382

Showing the most recent 10 out of 1396 publications